Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant

Bone Marrow Transplantation
B E ShawN H Russell

Abstract

Disease relapse following an allogeneic transplant remains a major cause of treatment failure, often with a poor outcome. Second allogeneic transplant procedures have been associated with high TRM, especially with myeloablative conditioning. We hypothesized that the use of reduced-intensity conditioning (RIC) would decrease the TRM. We performed a retrospective national multicentre analysis of 71 patients receiving a second allogeneic transplant using RIC after disease relapse following an initial allogeneic transplant. The majority of patients had leukaemia/myelodysplasia (MDS) (N=57), nine had lymphoproliferative disorders, two had myeloma and three had myeloproliferative diseases. A total of 25% of patients had unrelated donors. The median follow-up was 906 days from the second allograft. The predicted overall survival (OS) and TRM at 2 years were 28 and 27%, respectively. TRM was significantly lower in those who relapsed late (>11 months) following the first transplant (2 years: 17 vs 38% in early relapses; P=0.03). Two factors were significantly associated with a better survival: late relapse (P=0.014) and chronic GVHD following the second transplant (P=0.014). These data support our hypothesis that the second RIC allograf...Continue Reading

References

Oct 6, 2000·Bone Marrow Transplantation·R H CollinsP Parker
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BosiUNKNOWN Acute Leukemia Working Party of the European Blood and Marrow Transplant Group
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John E LevineRobert H Collins
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katharine BransonStephen Mackinnon
Mar 21, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Carol Ann HuffRichard J Jones
Jan 16, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Martha L ArellanoEdmund K Waller
Apr 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bronwen E ShawNigel H Russell
Sep 25, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marco MielcarekPaul J Martin

❮ Previous
Next ❯

Citations

Dec 7, 2011·Archivum Immunologiae Et Therapiae Experimentalis·H Joachim Deeg, Matthias Bartenstein
May 27, 2009·Current Opinion in Hematology·Lisa M ArfonsHillard M Lazarus
Sep 8, 2011·Current Opinion in Hematology·Betul Oran, Marcos de Lima
Nov 19, 2010·Expert Review of Hematology·A John Barrett, Minoo Battiwalla
Oct 6, 2015·Bone Marrow Transplantation·R VrhovacUNKNOWN Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Dec 8, 2015·Bone Marrow Transplantation·M Christopeit
Oct 21, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rachel B SalitColleen Delaney
Aug 11, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Romain GuièzeIbrahim Yakoub-Agha
Oct 16, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christine N DuncanMohamed L Sorror
Apr 3, 2010·Hematology/oncology Clinics of North America·Matthias Bartenstein, H Joachim Deeg
Sep 15, 2015·Bone Marrow Transplantation·T RuutuUNKNOWN European Society for Blood and Marrow Transplantation (EBMT)
Mar 16, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Hasan Sami Göksoy, Mutlu Arat
Mar 31, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ibraheem H MotabiJohn F DiPersio
Mar 15, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Swati NaikRobert Krance
Jul 13, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J O BayUNKNOWN Société Française de Greffe de Moelle et de Thérapie Cellulaire
Jul 5, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Katayoun RezvaniRichard Szydlo
Jun 19, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Brian T HillEdward Copelan
Jul 5, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jessica GorgeisMelhem Solh
Aug 7, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maximilian ChristopeitChristoph Schmid
Dec 29, 2016·Experimental Hematology·Guillermo OrtiDavid Valcarcel
Oct 27, 2009·Bone Marrow Transplantation·B N SavaniK Rezvani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.